The median survival time with intensified chemotherapy was approximately 1 year in patients with aggressive ATL, including acute and lymphoma types. Allogeneic SCT promises to prolong survival in patients with aggressive ATL.
showed that patients with stage II or III MM, and at least one osteolytic lesion benefit from BP therapy administered monthly for 24 months. However, the benefit of prolonging BP treatment beyond 24 months is not clear. Ali et al. 3 studied the effects of long-term BP administration for up to 6 years, and showed that bone events can occur following 2 years of treatment and that the tolerance is generally good. However, osteonecrosis of the jaw has been reported recently as a severe dose and time-dependent related adverse effect. 4 The Mayo Clinic has recently published a consensus for the use of BP in MM, proposing, after 2 years of treatment, to decrease the rate of BP injections from one per month to one every 3 months Figure 1 Event-free survival of BP1 and BP3 patients. Event-free survival was defined as the time in months between the study entry and an event (a skeletal event or myeloma progression). The occurrence of events was estimated according to the Kaplan-Meier method, and the log-rank test was performed to compare BP1 and BP3 patients (P ¼ 0.82).
Letters to the Editor in patients with active disease; to discontinue BP in patients who have achieved a response and/or are in a stable plateau phase of their MM. 5 We decided to conduct a 12 month, prospective and open trial, whose primary objective was to observe changes in biologic markers of bone remodeling in two groups of MM patients with stable disease; one receiving BP injections every month and the other every 3 months. Our hypothesis was that bone markers would not be modified when spacing BP injections from one monthly to one every 3 months.
From February 2004 to August 2005, all MM patients with stable disease, consulting at Cochin Hospital (Paris) and under zoledronate or pamidronate treatment, were screened to participate in the study. Stable myeloma was defined as patients whose MM was in very good partial response or in partial response. 6 Excluded from the study were, patients o18 years old, stage I MM or MGUS, MM with osteopenia without any osteolytic lesion, and MM in progression and patients receiving dexamethasone (because of its osteopenic effect). Consenting patients were allocated to two treatment groups. Group 1 (BP1): patients who had received BP for less than 24 months -they continued BP infusion monthly; Group 2 (BP3): patients who had received BP for more than 24 months -they were switched to receive BP once every 3 months. The median time of BP administration was 24.5 months (range, 24-67 months) for BP3 and 18 months for BP1 patients (range, 6-24 months). Patients received zoledronate, 4 mg per injection, during 1 year, except for patients with a clearance of creatinine o60 ml/min (25% of BP1 and 24% of BP3 patients), who were treated with pamidronate (60 mg). Normalization of vitamin D level was checked before inclusion. Cholecalciferol (Uvedose), 100 000 UI per os, was given every 3 months to patients with 3 , with a calcium supplement of 500 mg to 1 g according to nutritional regimen. All skeletal events were reported from the time of inclusion. When myeloma relapsed, chemotherapy was reintroduced and BP administered again monthly in BP3 patients. Biologic markers of bone remodeling, including osteocalcin (reflecting osteoformation), blood crosslaps CTX and urinary levels of deoxypyridolinuria (DPDu) (markers of osteolysis), were measured monthly in both groups during 1 year, starting from the date of inclusion in the study. The levels of CTX, osteocalcin and DPDu of BP1 patients at inclusion (baseline values) were compared with those of BP3 patients at inclusion. For each patient, the values of each of the three markers were compared every month with their baseline level.
Forty-one patients were included: 29 patients in the BP1 group and 12 in the BP3 group. Table 1 summarizes the main characteristics of these 41 patients. There was no difference at inclusion between the two groups concerning age, isotype of the monoclonal immunoglobulin, Durie and Salmon classification, bone disease status, number of previous lines of treatments and response status of the disease. Five BP1 patients and one BP3 patient suffered from skeletal events during the study: one BP1 had a lytic lesion of cervical vertebra C3 that required radiotherapy, four BP1 and one BP3 patients had vertebral fractures despite BP infusion, with a median delay of apparition of 21.7 months (range, 7-28.9 months) for BP1 and 5.6 months for BP3 patients.
The baseline levels of DPDu, in BP1 and BP3 patients, were not different from normal values measured in premenopausal women (n ¼ 36, Table 2 ). In contrast, osteocalcin and CTX baseline levels in BP1 and BP3 patients were significantly below the normal range (Po0.0001). There was no difference for CTX (P ¼ 0.66), DPDu (P ¼ 0.42) and osteocalcin (P ¼ 0.84) between BP1 and BP3 groups at inclusion. For BP1 patients, CTX, DPDu and osteocalcin were not modified at 1 year compared to baseline (Table 3) . CTX (P ¼ 0.11) and DPDu (P ¼ 0.30) levels were not significantly different in BP3 patients at the inclusion and 1 year after. However, serum osteocalcin significantly increased in BP3 patients over 1 year (P ¼ 0.007). There was no difference between BP1 and BP3 patients in event-free survival (EFS) from the beginning of the protocol (median EFS of 25 months for BP1 and of 25.8 months for BP3 (P ¼ 0.82)) ( Figure 1) . Osteonecrosis of the jaw occurred in one BP1 patient after 30 months of uninterrupted infusion of zoledronic acid. There was no exacerbation of renal insufficiency during BP infusion.
We report here the effect of spacing BP infusions every 3 months on bone remodeling, as assessed by the measurement of biochemical markers of bone turnover. CTX was selected as a marker of bone resorption, as it accurately reflects osteoclastic activity and the extent of bone disease in MM, given that the sRANKL/OPG ratio that is increased in MM patients, correlates with CTX levels. 7, 8 We first found that CTX and osteocalcin levels at baseline (in MM patients treated with bisphosphonates) were below the range of normal values of CTX measured in controls. This probably reflects the anti-resorptive effect of BP, since all patients had previously received BP. It has been shown that osteoclastic markers are elevated in MM patients at diagnosis, compared to controls, and decrease after ASCT and after thalidomide/dexamethasone treatment. 7, 8 On the other hand, osteoblasts remain functionally exhausted in patients with relapsed or refractory MM. Osteocalcin, a marker of osteoformation, was chosen to reflect this activity. Very interestingly, we observed that osteocalcin significantly increased in BP3 patients after 1 year. While the anti-resorptive activity of BP is well documented, it has not been demonstrated that they influence osteoformation markers. The reasons of this increase in osteocalcin levels are not clear.
Finally, we did not find any effect of spacing BP injections every 3 months either on the frequency of skeletal related events, or on osteoclastic bone marker remodeling (CTX and DPDu) with a follow-up of 1 year. Moreover, economic costs are not negligible, as one perfusion of zoledromic acid costs roughly 300A.
In conclusion, our study may suggest that, in stable MM beyond 2 years of BP treatment, osteoclastic bone markers are Table 2 Biologic markers of bone remodeling at baseline in BP1 and BP3 patients Blood samples were collected between 08:00 and 09:30 hours after an overnight fast and were immediately centrifuged at 41C and stored at À201C within 1 h after centrifugation. A fasting 2 h morning urine sample was also collected and stored at -201C until assayed. Each marker was collected each month, before the BP injection. Serum osteocalcin was measured with a human two-site ELISA N-MID osteocalcin (Nordik Bioscience), which detects the N-terminal midfragment (aminoacids 1-43) in addition to the intact serum osteocalcin (aminoacids 1-49). The detection limit is 2.0 ng/ml. The intra-and interassay coefficients of variations (CVs) were below 4%. The serum crosslaps one-step ELISA (Nordik Bioscience) is an immunoassay specific for the amino sequence EKAHD-b-GGR, where the aspartic residue is b-isomerized. This epitope derives from the C-terminal telopeptide region of type I collagen. The detection limit is 35 pmol/l. The intra-and interassay CVs were below 9%. Urinary free deoxypyridinoline (DPD) was determined with an ELISA method using a monoclonal antibody, which does not interact with cross-linked peptides (Pyrilinks-D Metra Biosystems). The intra-and interassay CVs were below 10%. The concentrations are expressed relative to those of urinary creatinine concentration determined on a Modular PP (Roche Diagnostics). The reference values for each of these markers are based on 36 premenopausal women's values. Differences between patients and controls, and between BP1 and BP3 patients' baseline values of the studied parameters were evaluated using the unpaired t-test.
steady in patients receiving BP every 3 months instead of each month. However, because of the small size of the study, the power of statistical tests may be limited. These results should be confirmed in larger and randomized studies, where MM patients with stringent complete response, complete response, or very good partial response and beyond 24 months of BP treatment, would be randomized between two arms: administration of BP every 3 months or abstention. 
